Recombinant Mouse Interleukin-33/IL-33 Protein

Catalog Number: PKSM041090

Note: Centrifuge before opening to ensure complete recovery of vial contents.

| Description | |
|----------------|--|
| Species | Mouse |
| Source | E.coli-derived Mouse Interleukin-33/IL-33 protein Ser109-Ile266, with an C-terminal |
| | His |
| Calculated MW | 18.5 kDa |
| Observed MW | 17-25 kDa |
| Accession | Q8BVZ5 |
| Bio-activity | Measure by its ability to induce proliferation in D10.G4.1 cells. The ED_{50} for this |
| | effect is <40 pg/mL. The specific activity of recombinant mouse IL-33 is > 2 x 10^7 IU/mg. |
| Properties | |
| Purity | > 98 % as determined by reducing SDS-PAGE. |
| Endotoxin | < 0.1 EU per µg of the protein as determined by the LAL method. |
| Storage | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80 |
| | °C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of |
| | reconstituted samples are stable at $< -20^{\circ}$ C for 3 months. |
| Shipping | This product is provided as lyophilized powder which is shipped with ice packs. |
| Formulation | Lyophilized from sterile PBS, pH 7.4. |
| | Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants |
| | before lyophilization. |
| | Please refer to the specific buffer information in the printed manual. |
| Reconstitution | Please refer to the printed manual for detailed information. |
| Data | |

kDa 75-63-48-35-25-17-

> 98 % as determined by reducing SDS-PAGE.

Background

Elabscience®

Mouse Interleukin 33 (IL-33) is a 30 kDa proinflammatory cytokine which may also regulates gene transcription in producer cells. IL-33 is constitutively expressed in smooth muscle and airway epithelia. IL-33 was identified based on sequence and structural homology with IL-1 family cytokines. It is up-regulated in arterial smooth muscle, dermal fibroblasts, and keratinocytes following IL-1 alpha or IL-1 beta stimulation. IL-33 is structurally related to IL-1, which induces helper T cells to produce type 2 cytokines and acts through the receptor IL1RL-1. BindingIL-33 to this receptor activates NF-kappa-B and MAP kinases and induces in vitro Th2 cells to produce cytokines. In vivo, IL-33 induces the expression of IL-4, IL-5, IL-13 and also leads to severe pathological changes in mucosal organs.